Volume 6.05 | Feb 13

Prostate Cell News 6.05 February 13, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
 
TOP STORY
A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer
Elucidating the determinants of aggressiveness in lethal prostate cancer may stimulate therapeutic strategies that improve clinical outcomes. Scientists used experimental models and clinical databases to identify GATA2 as a regulator of chemotherapy resistance and tumorigenicity in this context. [Cancer Cell]
Abstract | Graphical Abstract
New TeSR™-E8™ is Here For Feeder-Free Culture of Human ES Cells and iPS Cells
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Coactivator SRC-2-Dependent Metabolic Reprogramming Mediates Prostate Cancer Survival and Metastasis
Researchers determined that upregulation of the oncogenic transcriptional coregulator steroid receptor coactivator 2 (SRC-2), also known as NCOA2, drives glutamine-dependent de novo lipogenesis, which supports tumor cell survival and eventual metastasis. [J Clin Invest] Full Article

Aldehyde Dehydrogenase Is Regulated by Beta-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells
Scientists show that aldehyde dehydrogenase activity is indicative of radioresistant prostate progenitor cells with an enhanced DNA repair capacity and activation of epithelial-mesenchymal transition. [Cancer Res] Abstract

Discovery of CTCF-Sensitive Cis-Spliced Fusion RNAs between Adjacent Genes in Human Prostate Cells
In transcriptome analyses of 28 prostate normal and cancer samples, 30% fusion RNAs on average are the transcripts that contain exons belonging to same-strand neighboring genes. To validate this finding and to better understand the phenomenon, scientists used LNCaP, a prostate cell line as a model, and identified 16 additional cis-splicing between adjacent genes events by silencing transcription factor CTCF and paired-end RNA sequencing. [PLoS Genet] Full Article

Ethanol Extract of Remotiflori radix Induces Endoplasmic Reticulum Stress-Mediated Cell Death through AMPK/mTOR Signaling in Human Prostate Cancer Cells
Scientists used the ethanol extract of R. radix (ERR) and the PC-3 and DU145 prostate cancer cell lines in this study. They found that greater than 100 μg/mL ERR caused dose- and time-dependent cell death. [Sci Rep] Full Article

A Genetic Variant of MDM4 Influences Regulation by Multiple MicroRNAs in Prostate Cancer
Scientists show using reporter gene assays and endogenous MDM4 expression analyses that microRNA (miR)-191-5p and miR-887 have a specific affinity for the rs4245739 SNP C-allele in prostate cancer. These miRNAs do not affect MDM4 mRNA levels but rather inhibit its translation in C-allele containing PC3 cells but not in LNCaP cells homozygous for the A-allele. [Endocr Relat Cancer] Abstract

Regulation of the ITGA2 Gene by Epigenetic Mechanisms in Prostate Cancer
Bisulphite sequencing of the ITGA2 promoter was used to assess methylation in formalin-fixed paraffin-embedded prostate tumor specimens and prostate cancer cell lines, PC3, 22Rv1 and LNCaP. [Prostate] Abstract

Tomato Paste Alters NF-κB and Cancer-Related mRNA Expression in Prostate Cancer Cells, Xenografts, and Xenograft Microenvironment
Researchers investigated whether tomato paste could modulate nuclear factor-κB (NF-κB) activity and cancer-related gene expression in human derived prostate cancer cells (PC3) and PC3 xenografts. [Nutr Cancer] Abstract

CLINICAL RESEARCH

Phase I Trial of a Cancer Vaccine Consisting of 20 Mixed Peptides in Patients with Castration-Resistant Prostate Cancer: Dose-Related Immune Boosting and Suppression
Researchers evaluated the safety and immune dynamics of a cancer vaccine consisting of 20 mixed peptides designed to induce cytotoxic T lymphocytes (CTLs) against 12 different tumor-associated antigens in patients with castration-resistant prostate cancer. [Cancer Immunol Immunother] Abstract

Prospective Evaluation of Low-Dose Ketoconazole plus Hydrocortisone in Docetaxel Pre-Treated Castration-Resistant Prostate Cancer Patients
Chemotherapy-naïve patients treated with attenuated doses of ketoconazole had PSA response rate of 21-62%. Researchers hypothesized that low-dose ketoconazole would likewise possess efficacy and tolerability in the castration-resistant prostate cancer post-chemotherapy state. [Prostate Cancer Prostatic Dis] Abstract

Free Sample: TeSR™2 Defined, Feeder-Free and Xeno-Free Human ES and iPS Cell Medium
 
REVIEWS
Dietary Polyphenols in Prevention and Treatment of Prostate Cancer
The authors review the health benefits of selected dietary polyphenols in prostate cancer, especially focusing on the subclasses of polyphenols, which have a great effect on disease prevention and treatment. [Int J Mol Sci] Abstract | Download Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
Aduro Meets Development Milestone in Immuno-Oncology Collaboration with Janssen for Treatment of Prostate Cancer
Aduro Biotech, Inc. announced that it has achieved its first milestone under its collaboration with Janssen Biotech, Inc. by initiating toxicology studies to support an investigational new drug application for ADU-741, an immuno-oncology product candidate for the treatment of prostate cancer. [Aduro Biotech, Inc.] Press Release

Damon Runyon Cancer Research Foundation Grants Prestigious Fellowship, Breakthrough Scientist Awards
The Damon Runyon Cancer Research Foundation named six new recipients of the Damon Runyon-Dale F. Frey Award for Breakthrough Scientists. Each awardee will receive $100,000 to be used toward their research. [The Damon Runyon Cancer Research Foundation] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration).
Request your free copy.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Regenerative Medicine & Stem Cell (RMSC) 2015
March 19-21, 2015
Busan, South Korea

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Cancer Biology (Brigham & Women’s Hospital – Harvard Medical School)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Director – Vector Production (Sangamo BioSciences, Inc.)

Senior Process Development Engineer (Sangamo BioSciences, Inc.)

Postdoctoral Research – Scientist Metabolic Adaptation in Treatment Resistant Prostate Cancer (Cancer Research UK Beatson Institute in Glasgow)

Postdoctoral Position – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic)

Postdoctoral Researcher – Prostate Cancer (University of Pennsylvania)

Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us